VIRX (Viracta Therapeutics) Total Receivables: $0.00 Mil (As of Sep. 2024)


What is Viracta Therapeutics Total Receivables?

Viracta Therapeutics VIRX Total Receivables is $0.00 Mil as of Sep. 2024.

Viracta Therapeutics's Total Receivables for the quarter that ended in Sep. 2024 was $0.00 Mil.

Viracta Therapeutics Total Receivables Related Terms

Viracta Therapeutics Total Receivables Historical Data

* Premium members only.

The historical data trend for Viracta Therapeutics's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viracta Therapeutics Total Receivables Chart

Viracta Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Receivables
0.00 0.00 0.91 0.28

Viracta Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.28 0.00 0.00 0.00

Viracta Therapeutics Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $0.00 Mil mean?
Viracta Therapeutics (VIRX) has a Total Receivables of $0.00 Mil as of Sep. 2024. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Viracta Therapeutics and its competitors.
Is Viracta Therapeutics' Total Receivables too high?
Viracta Therapeutics' current Total Receivables is $0.00 Mil.
How does Viracta Therapeutics' Total Receivables compare to TSOI and CYTOF?
Viracta Therapeutics' Total Receivables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Viracta Therapeutics and its competitors. Viracta Therapeutics's current Total Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viracta Therapeutics stock overvalued right now?
Viracta Therapeutics (VIRX) has a current Total Receivables of $0.00 Mil. The current Total Receivables is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Viracta Therapeutics (VIRX), the current Total Receivables is $0.00 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viracta Therapeutics Business Description

Address 2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.